Merck Serono at a glance
| Therapeutic Area | Key indications |
Oncology Erbitux® (cetuximab) UFT® (tegafur-uracil)
| - Metastatic colorectal cancer - Locally advanced squamous cell carcinoma of the head and neck - Recurrent and/or metastatic squamous cell carcinoma of the head and neck - Metastatic colorectal cancer |
Neurodegenerative Diseases Rebif® (interferon beta-1a) | - Relapsing multiple sclerosis |
Fertility Complete portfolio of drugs including gonadotropic hormones used in the treatment of infertility
| - Various indications in the treatment of infertility |
Endocrinology Saizen® (somatropin for injection) Serostim® (somatropin for injection) Kuvan® (sapropterin dihydrochloride) EGRIFTA™ (tesamorelin for injection) | - Child and adult growth hormone deficiency - Children born small for gestational age - Turner syndrome - Chronic renal failure - HIV-associated wasting
- Treatment of hyperphenylalaninemia (HPA) in phenylketonuria (PKU) or BH4 deficient patients - Excess abdominal fat in HIV-infected patients with lipodystrophy (abdominal lipohypertrophy)
|
CardioMetabolic Care Glucophage® (metformin hydrochloride) Concor® family of products containing bisoprolol Euthyrox® (levothyroxine sodium), thyroid hormones | - Type II diabetes - Cardiovascular diseases (hypertension, coronary artery disease, chronic heart failure) - Thyroid disorders |
| € million | 2010 | 2009 | ∆ in % |
| Total revenues | 5,754 | 5,345 | 7.6 |
| Gross margin | 4,793 | 4,485 | 6.9 |
| R&D | 1,167 | 1,184 | -1.4 |
| Operating result | 565 | 355 | 59 |
| Exception items | 69 | -40 | - |
| Free cash flow | 1,298 | 864 | 50 |
| Underlying free cash flow | 1,308 | 867 | 51 |
| ROS in % | 9.8 | 6.6 |
